SLS Projected Dividend Yield

SELLAS Life Sciences Group Inc ( NASDAQ : SLS )

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. Co. is focused on the development of novel therapeutics for a range of cancer indications. Co.'s product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types.

21 YEAR PERFORMANCE RESULTS

SLS Dividend History Detail
SLS Dividend News
SLS Competitors News
# of Shares: 0 Closing Price: 1.31 Current Market Value: 0.00 Cost Basis: 0.00 Date Acquired:
Dividend Cash Flow
Year Annual Dividend Dividend Growth # of Shares Annual Dividend Income Yield On Cost %
2014 0.00 0% 0 $ 0.00 0.00%
2015 0.00 0% 0 $ 0.00 0.00%
2016 0.00 0% 0 $ 0.00 0.00%
2017 0.00 0% 0 $ 0.00 0.00%
2018 0.00 0% 0 $ 0.00 0.00%
2019 0.00 0% 0 $ 0.00 0.00%
2020 0.00 0% 0 $ 0.00 0.00%
2021 0.00 0% 0 $ 0.00 0.00%
2022 0.00 0% 0 $ 0.00 0.00%
2023 0.00 0% 0 $ 0.00 0.00%
2024 0.00 0% 0 $ 0.00 0.00%
2025 0.00 0% 0 $ 0.00 0.00%
2026 0.00 0% 0 $ 0.00 0.00%
2027 0.00 0% 0 $ 0.00 0.00%
2028 0.00 0% 0 $ 0.00 0.00%
2029 0.00 0% 0 $ 0.00 0.00%
2030 0.00 0% 0 $ 0.00 0.00%
2031 0.00 0% 0 $ 0.00 0.00%
2032 0.00 0% 0 $ 0.00 0.00%
2033 0.00 0% 0 $ 0.00 0.00%
2034 0.00 0% 0 $ 0.00 0.00%
2035 0.00 0% 0 $ 0.00 0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection)
0.00
Year
Declaration Date
Ex-Dividend Date
Record Date
Payable Date
Dividend $ Amount
Total:
0.0000
X
Search Dividend Investor